Naaju Breaking News, Live Updates, Latest Headlines, Viral News, Top Stories, Trending Topics, Videos
[ad_1]
the candidate vaccine Abdala against the coronavirus, developed by the Center for Genetic Engineering and Biotechnology, has shown a 92.2% efficiency in the first analyzes of the third and final phase of clinical trialsstate media reported on Monday.
These data were announced, without further details, in the program State television round table and the information is expected to be developed shortly.
Abdala, one of the five formulas against SARS-CoV-2 studied in Cuba, is a subunit vaccine based on the S protein receptor binding site (RBD) of the virus, and has an application schedule of three doses given 14 days apart.
The World Health Organization (WHO) establishes that for a vaccine candidate to be considered a vaccine, it must demonstrate efficacy equal to or greater than 50%.
The third phase of Abdala’s clinical trials began in mid-March in the eastern provinces of Santiago, Guantanamo and Granma, with the participation of 48,000 volunteers aged 19 to 80 years and under the international standard of a multicenter, randomized, double-blind, placebo-controlled study.
The result was presented today by CIGB officials to the Cuban President, Miguel Diaz Canel, who according to a state television report said that it is “a great vaccine” and “an event which increases tenfold the pride of this country and its scientists”.
The news comes two days after news broke that another of Cuba’s potential vaccines, Soberana 02, from the Finlay Vaccine Institute, achieved 62% efficacy in the preliminary results of the final phase of clinical trials, entirely carried out in Havana with 44,010 volunteers.
It is expected that, as the IFV will do with Sovereign 02, ICOLD immediately requests emergency use authorization for Abdala from the State Control Center for Drugs, Equipment and Medical Devices (Cecmed), the regulatory body of Cuba.
The first of the two to obtain such authorization would become the first vaccine against the coronavirus developed in Latin America.
So many Sovereign 02 like Abdala have already been administered to tens of thousands of Cubans under the figure of intervention studies in health and in parallel with clinical trials.
According to official figures, just over two million Cubans, out of a population of 11 million, have received at least one dose of these formulas.
Cuba is not a member of the Covax mechanism created so that low- and middle-income countries have access to vaccines, and did not purchase them on the international market.
The country, which has been going through the third and worst wave of infections since January, today recorded a new record of daily infections and has accumulated 169,365 positives and 1,170 deaths from covid-19 to date.
.
[ad_2]
Source link
